vs
Prestige Consumer Healthcare Inc.（PBH）とフォトロニクス（PLAB）の財務データ比較。上の社名をクリックして会社を切り替えられます
Prestige Consumer Healthcare Inc.の直近四半期売上が大きい（$283.4M vs $210.4M、フォトロニクスの約1.3倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 10.9%、差は5.6%）。Prestige Consumer Healthcare Inc.の前年同期比売上増加率が高い（-2.4% vs -5.5%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $25.2M）。過去8四半期でPrestige Consumer Healthcare Inc.の売上複合成長率が高い（1.2% vs -3.8%）
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
フォトロニクスは米国の半導体フォトマスクメーカーで、2009年時点で世界第3位のフォトマスクサプライヤーです。電子ビームイニシアチブのメンバーでもあり、半導体製造に不可欠なフォトマスクを供給し、チップ製造の回路パターン転写工程を支えています。
PBH vs PLAB — 直接比較
損益計算書 — Q3 FY2026 vs Q3 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $283.4M | $210.4M |
| 純利益 | $46.7M | $22.9M |
| 粗利率 | 55.5% | 33.7% |
| 営業利益率 | 29.1% | 22.9% |
| 純利益率 | 16.5% | 10.9% |
| 売上前年比 | -2.4% | -5.5% |
| 純利益前年比 | -23.5% | -32.4% |
| EPS（希薄化後） | $0.97 | $0.39 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $283.4M | — | ||
| Q3 25 | $274.1M | $210.4M | ||
| Q2 25 | $249.5M | $211.0M | ||
| Q1 25 | $296.5M | $212.1M | ||
| Q4 24 | $290.3M | $222.6M | ||
| Q3 24 | $283.8M | $211.0M | ||
| Q2 24 | $267.1M | $217.0M | ||
| Q1 24 | $277.0M | $216.3M |
| Q4 25 | $46.7M | — | ||
| Q3 25 | $42.2M | $22.9M | ||
| Q2 25 | $47.5M | $8.9M | ||
| Q1 25 | $50.1M | $42.9M | ||
| Q4 24 | $61.0M | $33.9M | ||
| Q3 24 | $54.4M | $34.4M | ||
| Q2 24 | $49.1M | $36.3M | ||
| Q1 24 | $49.5M | $26.2M |
| Q4 25 | 55.5% | — | ||
| Q3 25 | 55.3% | 33.7% | ||
| Q2 25 | 56.2% | 36.9% | ||
| Q1 25 | 57.3% | 35.6% | ||
| Q4 24 | 55.5% | 37.0% | ||
| Q3 24 | 55.5% | 35.6% | ||
| Q2 24 | 54.7% | 36.5% | ||
| Q1 24 | 54.8% | 36.6% |
| Q4 25 | 29.1% | — | ||
| Q3 25 | 29.1% | 22.9% | ||
| Q2 25 | 28.8% | 26.4% | ||
| Q1 25 | 29.8% | 24.6% | ||
| Q4 24 | 31.7% | 25.1% | ||
| Q3 24 | 29.7% | 24.7% | ||
| Q2 24 | 27.0% | 25.8% | ||
| Q1 24 | 29.7% | 26.6% |
| Q4 25 | 16.5% | — | ||
| Q3 25 | 15.4% | 10.9% | ||
| Q2 25 | 19.0% | 4.2% | ||
| Q1 25 | 16.9% | 20.2% | ||
| Q4 24 | 21.0% | 15.2% | ||
| Q3 24 | 19.2% | 16.3% | ||
| Q2 24 | 18.4% | 16.7% | ||
| Q1 24 | 17.9% | 12.1% |
| Q4 25 | $0.97 | — | ||
| Q3 25 | $0.86 | $0.39 | ||
| Q2 25 | $0.95 | $0.15 | ||
| Q1 25 | $1.00 | $0.68 | ||
| Q4 24 | $1.22 | $0.54 | ||
| Q3 24 | $1.09 | $0.55 | ||
| Q2 24 | $0.98 | $0.58 | ||
| Q1 24 | $0.98 | $0.42 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $62.4M | $575.8M |
| 総負債低いほど良い | $1.0B | $16.0K |
| 株主資本純資産 | $1.8B | $1.1B |
| 総資産 | $3.5B | $1.8B |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | 0.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.4M | — | ||
| Q3 25 | $119.1M | $575.8M | ||
| Q2 25 | $139.5M | $558.4M | ||
| Q1 25 | $97.9M | $642.2M | ||
| Q4 24 | $50.9M | $640.7M | ||
| Q3 24 | $51.5M | $606.4M | ||
| Q2 24 | $34.3M | $559.9M | ||
| Q1 24 | $46.5M | $521.5M |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | $16.0K | ||
| Q2 25 | $992.7M | $19.0K | ||
| Q1 25 | $992.4M | $21.0K | ||
| Q4 24 | $992.0M | $25.0K | ||
| Q3 24 | $1.1B | $28.0K | ||
| Q2 24 | $1.1B | $2.5M | ||
| Q1 24 | $1.1B | $2.7M |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.8B | $1.1B | ||
| Q2 25 | $1.9B | $1.1B | ||
| Q1 25 | $1.8B | $1.1B | ||
| Q4 24 | $1.8B | $1.1B | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.7B | $1.0B | ||
| Q1 24 | $1.7B | $1.0B |
| Q4 25 | $3.5B | — | ||
| Q3 25 | $3.4B | $1.8B | ||
| Q2 25 | $3.4B | $1.7B | ||
| Q1 25 | $3.4B | $1.7B | ||
| Q4 24 | $3.3B | $1.7B | ||
| Q3 24 | $3.3B | $1.6B | ||
| Q2 24 | $3.3B | $1.6B | ||
| Q1 24 | $3.3B | $1.6B |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | 0.00× | ||
| Q2 25 | 0.54× | 0.00× | ||
| Q1 25 | 0.54× | 0.00× | ||
| Q4 24 | 0.55× | 0.00× | ||
| Q3 24 | 0.61× | 0.00× | ||
| Q2 24 | 0.65× | 0.00× | ||
| Q1 24 | 0.68× | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.3M | $50.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $75.3M | $25.2M |
| FCFマージンFCF / 売上 | 26.6% | 12.0% |
| 設備投資強度設備投資 / 売上 | 1.1% | 11.8% |
| キャッシュ転換率営業CF / 純利益 | 1.68× | 2.19× |
| 直近12ヶ月FCF直近4四半期 | $267.2M | $64.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.3M | — | ||
| Q3 25 | $57.5M | $50.1M | ||
| Q2 25 | $79.0M | $31.5M | ||
| Q1 25 | $61.8M | $78.5M | ||
| Q4 24 | $65.1M | $68.4M | ||
| Q3 24 | $69.8M | $75.1M | ||
| Q2 24 | $54.8M | $76.5M | ||
| Q1 24 | $66.9M | $41.5M |
| Q4 25 | $75.3M | — | ||
| Q3 25 | $55.4M | $25.2M | ||
| Q2 25 | $78.2M | $-29.1M | ||
| Q1 25 | $58.4M | $43.3M | ||
| Q4 24 | $63.5M | $25.2M | ||
| Q3 24 | $67.8M | $50.7M | ||
| Q2 24 | $53.6M | $56.5M | ||
| Q1 24 | $63.8M | $-1.8M |
| Q4 25 | 26.6% | — | ||
| Q3 25 | 20.2% | 12.0% | ||
| Q2 25 | 31.3% | -13.8% | ||
| Q1 25 | 19.7% | 20.4% | ||
| Q4 24 | 21.9% | 11.3% | ||
| Q3 24 | 23.9% | 24.0% | ||
| Q2 24 | 20.1% | 26.0% | ||
| Q1 24 | 23.0% | -0.8% |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.8% | 11.8% | ||
| Q2 25 | 0.3% | 28.7% | ||
| Q1 25 | 1.2% | 16.6% | ||
| Q4 24 | 0.5% | 19.4% | ||
| Q3 24 | 0.7% | 11.6% | ||
| Q2 24 | 0.4% | 9.2% | ||
| Q1 24 | 1.1% | 20.0% |
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.36× | 2.19× | ||
| Q2 25 | 1.66× | 3.55× | ||
| Q1 25 | 1.23× | 1.83× | ||
| Q4 24 | 1.07× | 2.02× | ||
| Q3 24 | 1.28× | 2.18× | ||
| Q2 24 | 1.12× | 2.11× | ||
| Q1 24 | 1.35× | 1.59× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
PLAB
| High End Integrated Circuits | $53.6M | 25% |
| High End Flat Panel Displays | $53.5M | 25% |
| KR | $43.7M | 21% |
| Other | $42.1M | 20% |
| Mainstream Flat Panel Displays | $9.1M | 4% |
| Transferred At Point In Time | $8.4M | 4% |
